Kyowa Kirin Co., Ltd. (TYO:4151)

Market Cap	1.31T +3.7%
Revenue (ttm)	532.32B +10.4%
Net Income	86.11B +135.5%
EPS	164.48 +135.5%
Shares Out	523.58M
PE Ratio	15.27
Forward PE	14.31
Dividend	70.00 (2.79%)
Ex-Dividend Date	Dec 29, 2026

Volume	1,267,600
Open	2,530.50
Previous Close	2,533.00
Day's Range	2,497.00 - 2,531.00
52-Week Range	2,109.00 - 2,912.00
Beta	0.16
Analysts	Sell
Price Target	2,263.64 (-9.85%)
Earnings Date	Nov 2, 2026

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodular...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1949
• Employees: 5,161
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4151

Financial Performance

In 2025, Kyowa Kirin's revenue was 496.83 billion, an increase of 0.26% compared to the previous year's 495.56 billion. Earnings were 67.04 billion, an increase of 11.98%.

Analyst Summary

According to 11 analysts, the average rating for 4151 stock is "Sell." The 12-month stock price target is ¥2,264, which is a decrease of -9.85% from the latest price.

Price Target

¥2,264

(-9.85% downside)

Analyst Consensus: Sell

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error